The Center for Drug Evaluation (CDE) in China has issued a draft proposal for “Technical Guidelines for Clinical Trials of Chimeric Antigen Receptor (CAR)-T Cell Therapy for Malignant Tumors of the Lymphatic and Hematological System.” These guidelines are designed to provide a framework for the design, protocol, and execution of clinical trials for CAR-T cell products, which are increasingly significant in the treatment of various cancers.<\/p>\n\n\n\n
The draft guidelines are particularly relevant for autologous CAR-T cell products, though they may also extend to allogeneic or universal CAR-T cells and other genetically modified lymphocyte products, such as CAR-NK and TCR-T cells. The malignant tumors targeted primarily include B-ALL, B-NHL, and MM, which have seen a concentration of clinical trials for CAR-T cell products.<\/p>\n\n\n\n
Recognizing the potential for adverse reactions such as cytokine release syndrome (CRS) and neurotoxicity, the guidelines emphasize the importance of a sponsor developing a clinical research and development plan that balances the potential benefits and safety risks of CAR-T therapy with disease staging and existing treatment options.<\/p>\n\n\n\n